OGEN News and Press, Oragenics Inc. From 03/18/24

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II ...

2024-03-17 08:20:00 ET Wall Street has reached a notable lull in the pace of quarterly releases. Still, investors are eagerly anticipating important announcements from FedEx ( NYSE: FDX ) and a set of prominent consumer brands, such as Nike ( NYSE: NKE ), Lululemon Athl...

Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten publi...

A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 2.4% to $31.03 on volume of 179,649,718 shares Vivani Medical Inc. (VANI) rose 270.3% to $3.74 on volume of 148,811,385 shares Nikola Corporation (NKLA) rose 1.7% to $0.7684 on volume of 121,...

A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 1.8% to $30.87 on volume of 148,760,969 shares Vivani Medical Inc. (VANI) rose 291.9% to $3.9579 on volume of 141,227,838 shares Nikola Corporation (NKLA) rose 2.6% to $0.7758 on volume of 10...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,00...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer to sell shares of its common stoc...

2024-02-12 16:47:23 ET More on Oragenics Financial information for Oragenics Read the full article on Seeking Alpha For further details see: Oragenics says CEO Murphy steps down from the role

Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company’s Chief...